The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication for malignant pleural mesothelioma (Japan Mesothelioma Interest Group 1101 Trial).
 
Seiki Hasegawa
Research Funding - Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kohei Yokoi
No Relationships to Disclose
 
Morihito Okada
Speakers' Bureau - Chugai Pharma; Covidien; Johnson & Johnson; Lilly; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Pfizer (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Fumihiro Tanaka
Honoraria - Lilly Japan
Speakers' Bureau - Lilly Japan
Research Funding - Lilly Japan
 
Mototsugu Shimokawa
Consulting or Advisory Role - Sysmex
 
Takashi Daimon
Honoraria - Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Ajinomoto; Astellas Pharma; Daiichi Sankyo; Eisai; Ferring; Ono Pharmaceutical; TERUMO
 
Takashi Nakano
No Relationships to Disclose